STE (72) ISRG (75) ZBH (71) SNN (58) ⌘ Pro Terminal →

Edwards Lifesciences Corporation (EW) — RQD Stock Rating Cockpit

$92.01 -2.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $91.81

Edwards Lifesciences Corporation (EW) earns a Roarable Rating of B+ (Buy) with 79/100 RQD Confidence. High-quality cash engine (78% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 79/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.1% avg 90D alpha vs SPY • 71.0% hit rate) →

ROARABLE B+ • BUY Cap $54.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EW Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Edwards Lifesciences Corporation (NYSE: EW) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 79/100 at a spot price of $92.01 (-2.57% 1D, market cap $54.44B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, EW ranks #18 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EW compare to STE and ISRG in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), EW carries a Roarable B+ (79/100 RQD), trailing P/E of 50.7x, gross margin of 78.0%, and ROIC of 12.5%. By comparison, STE (STERIS plc (Ireland)) holds a B grade (72/100 RQD, P/E 28.9x, ROIC 10.1%, cap $22.63B) and ISRG (Intuitive Surgical Inc.) posts a B grade (75/100 RQD, P/E 54.5x, ROIC 15.0%, cap $155.56B). Among the 5-stock peer group, ZBH leads on earnings multiple (26.4x) while ISRG leads on capital efficiency (15.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EW?

▼

Per EW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001099800), Edwards Lifesciences Corporation generated $6.07B in revenue (+11.5% YoY), $1.07B in net income, and $1.33B in free cash flow against $13.70B in total assets and $598.3M in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $91.81 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 22% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 79/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.1% avg 90D alpha vs SPY • 71.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EW)Realized 20D OHLCV Swing Band: ±5.5%

Deterministic 5-Pillar Attribution (79/100 Composite)

🔍 WHY EW SCORES 79/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (23% of score)

20D Institutional Volume Accumulation (±5.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (23% of score)

Altman Z-Score 12.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$85.27+3.5% Next Q

Q2 (-2Q)

Grade B+$88.29+2.9% Next Q

Q3 (-1Q)

Grade B+$90.82+1.3% Next Q

Current

Grade B+$92.01+8.1% Hist 90D α

Trajectory: B (71) → B+ (79)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EW Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 79/100 (B+) score, EW faces multiple-compression risk if 50.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 75.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($88.31) or 200D SMA ($85.53) invalidates the momentum regime and cuts Target Base ($100.70) toward Bear Floor ($75.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EW• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 79%NO 21%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

65.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

12.36>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE80% OF RANGE

L: $75$92.01H: $96

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (78% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 32 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on EW

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

12.5% ROIC with 78.0% gross margin and 2.45% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 12.36 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (73)

30/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like EW

✓Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.
✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (EW Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.42%📐 HORIZONTAL RANGE

2026-11-02O $91.78H $94.44L $91.78C $92.01VOL 4.68M

RES: $95.39SUP: $82.87SMA50: $88.31SMA200: $85.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EW Butterfly Map → + Track EW →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

36.7%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EW)

Health Care Rank #18 of 1016 ⚔️ STE vs EW Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EW vs. STE, ISRG, ZBH, SNN)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Edwards Lifesciences Corporation (EW) ranks #18 by composite RQD confidence (79/100, grade B+) and #36 by equity capitalization ($54.44B). Within this direct 5-issuer industry benchmark cohort, ZBH leads on earnings valuation at 26.4x trailing P/E, while ISRG leads on capital efficiency and profitability with 15.0% ROIC and 66.0% gross margin. EW currently leads its immediate peer cohort in composite quantitative strength at 79/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EW ACTIVE Edwards Lifesciences Corporation	B+	79/100	50.7x	78.0%	12.5%	-2.57%	$54.44B	Benchmark Subject
STE STERIS plc (Ireland)	B	72/100	28.9x	44.2%	10.1%	-2.16%	$22.63B	/ste-vs-ew →
ISRG Intuitive Surgical Inc.	B	75/100	54.5x	66.0%	15.0%	-3.73%	$155.56B	/isrg-vs-ew →
ZBH Zimmer Biomet Holdings Inc.	B-	71/100	26.4x	69.7%	4.6%	-3.03%	$18.59B	/zbh-vs-ew →
SNN Smith & Nephew SNATS Inc.	D+	58/100	32.8x	—	9.9%	-2.33%	$12.73B	/snn-vs-ew →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001099800

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Edwards Lifesciences Corporation (EW) reported GAAP revenue of $6.07B (+11.5% vs. FY2024 revenue of $5.44B , and +21.1% cumulative change since FY2023) , GAAP net income of $1.07B, operating cash flow of $1.60B, and free cash flow of $1.33B (+360.5% YoY). On the balance sheet, EW closed FY2025 with $13.70B in total assets against $598.3M in total debt (Altman Z-Score: 12.36, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.07B	$1.07B	$1.60B	$1.33B	$13.70B	$598.3M
FY2024 (FY)	2024-12-31	$5.44B	$4.17B	$542.3M	$289.9M	$13.06B	$597.7M
FY2023 (FY)	2023-12-31	$5.01B	$1.40B	$895.8M	$670.4M	$29.94B	$7.01B

3. EW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EW compare to STE and ISRG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EW?

Where is EW trading relative to its 50-day, 200-day, and 52-week technical levels?

EW last traded at $92.01 (-2.57% on volume of 6,044,702 shares), positioning the stock +4.19% above its 50-day simple moving average ($88.31) and +7.58% above its 200-day simple moving average ($85.53). Across its 52-week range of $74.66 to $96.29, EW sits at the 80.2% percentile with a 14-day RSI of 65.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.5% ($86.95 to $97.07).

EW Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell EW stock right now?

Edwards Lifesciences Corporation (EW) currently earns a Roarable Rating of B+ (Buy — BUY) with 79/100 RQD Confidence. High-quality cash engine (78% profit margin, 13% return on capital) with steady institutional support.

What is EW's 12-month price target and RQD AI Jury consensus?

EW's 12-month base price target is $100.7 (range $75.45 to $118.83), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: EW RQD Cockpit EW 12M Forecast EW Earnings & Move EW Dividends & DRIP EW Insiders & 13F EW Whale Options EW Profit Sankey EW News & Why

ROARABLE RATING BRIEF • RQD 79/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EW — Edwards Lifesciences Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:10:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EW scores 79 out of 100 (letter grade B+), labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 12.5% and an FCF yield of 2.45%. For a prospective investor, the high ROIC indicates the company generates solid returns on invested capital, while the low FCF yield means the stock is priced at a premium relative to current free cash generation; the valuation tradeoff is that upside depends on sustained cash growth.
Whale 13F Flow: 18 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The rating implies constructive institutional interest, though the underlying 13F holder detail is not itemized in the source data.
Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The moderate score suggests insider signaling is supportive but not a dominant driver.
Macro Regime Fit: 14 / 20. Per the Roarable RQD rating, beta is 1.08 with a sector-sensitivity read. For an investor, this means the stock moves roughly in line with the market, with moderate exposure to regime shifts.
Forensic Balance Sheet: 18 / 20. Per the Roarable RQD rating, the Altman Z-Score is 12.36, the Piotroski F-Score is 8/9, and Debt/Equity is 0.06. These readings point to a financially strong balance sheet with low leverage, which reduces downside from financing stress.

Overall, the rating's strongest support comes from balance-sheet quality and institutional flow; the main drag is the premium valuation relative to cash yield, which limits margin of safety at current levels.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$94.44	$54.44B	50.7	47.2	35.1	1.86	0%	1.08	$74.66 - $96.29	12.5%

Business

Edwards Lifesciences Corporation (EW) is a NYSE-listed issuer in the Health Care sector, classified under Industrial Specialties. Per the market data, the company reports a gross margin of 78% and an operating margin of 20.8%. The source data does not itemize specific products, customer segments, or revenue mix beyond the sector and industry classification.

Recent Catalysts & News Wire Analysis

The news wire contains six items, all flagged YELLOW by the source and classified as MARKET WIRE. Headlines reference Q3 results and cardio portfolio performance (Seeking Alpha), a consensus price target of $100.27 (MarketBeat), and Q3 estimate coverage (Yahoo Finance). Per the source headlines, these items concern market action, institutional positioning, and fundamental catalysts, but the article bodies are not included, so specific catalyst details are not available in source data. Risk watch items cannot be confirmed beyond the YELLOW flag. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Open Questions

What drove the FY 2024 net income ($4174.6M) well above revenue-adjacent years, and is it recurring?
What explains the FY 2023 debt figure ($7005.8M) relative to FY 2024 and FY 2025 ($597.7M and $598.3M)?
What are the reported EPS figures for each fiscal period, since all are listed as N/A?
What specific holders are behind the whale 13F accumulation signal, and what insider trades underlie the 12/20 insider score?
What are the actual Q3 results and catalyst details referenced in the news headlines?

EW Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Edwards Lifesciences Corporation (EW) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EW Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

Edwards Lifesciences Corporation (EW) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 9h ago

Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives

Seeking Alpha report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 12h ago

Is This the Right Time to Hold EW Stock in Your Portfolio?

TradingView report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 15h ago

Edwards Lifesciences (NYSE:EW) Stock Forecast & Analyst Predictions

Simply Wall St report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 18h ago

Edwards Lifesciences Corporation (NYSE:EW) Stock Has Consensus Price Target of $100.27

MarketBeat report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Yahoo Finance report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

FDA approval makes Edwards the only U.S. company with therapies to repair or replace mitral and tricuspid valves.

Stock Titan report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Edwards Lifesciences Corporation $EW Stock: Robeco Schweiz AG Grows Position

MarketBeat report covering Edwards Lifesciences Corporation (EW) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EW Bull vs. Bear Conversation Board — What's Your Call at $92.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EW 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $111.44 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EW (B+ • RQD 79/100) a Buy at $94.44?

Welcome to the EW (Edwards Lifesciences Corporation) Roar Pit. Current RQD Composite is 79/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Industrial Specialties. Bulls point to capital efficiency (12.5% ROIC), while bears focus on valuation multiple compression (50.7x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $79.33 (-16.0%)

Spot @ $94.44

Pump the brakes on EW — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EW, but look at what you are paying: 50.7x trailing P/E with 78.0% gross margins. Unless Edwards Lifesciences Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $107.66 (+14.0%)

Spot @ $94.44

EW cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EW, the market is fixating on short-term headline noise in Industrial Specialties and ignoring the balance sheet and cash flow trajectory. At $94.44 (52-wk range $74.66 - $96.29), any beat on forward guidance forces shorts and underweight funds to chase.